WT1: What has the last decade told us?

BioEssays

Volumn 21, Issue 3, 1999, Pages 191-202

  Little, Melissa H ^a   Holmes, Greg ^a,b   Walsh, Patrick ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE EXPRESSION REGULATION; GENE MUTATION; NEPHROBLASTOMA; TUMOR SUPPRESSOR GENE;

ANIMALS; DNA; DNA-BINDING PROTEINS; GENES, WILMS TUMOR; GENOTYPE; HUMANS; KIDNEY; MICE; PHENOTYPE; RNA; RNA-BINDING PROTEINS; SYNDROME; TRANSCRIPTION FACTORS; WILMS TUMOR; WT1 PROTEINS; ZINC FINGERS;

EID: 0033103967     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-1878(199903)21:3<191::AID-BIES3>3.0.CO;2-8     Document Type: Review

References (87)

1. Call K, Glaser T, Ito C, Buckler A, Pelletier J, Haber D, Rose E, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990;60:509-520.
2. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GAP. Homozygous deletion in Wilms tumours of a gene identified by chromosome jumping. Nature 1990;343:774-778.
3. Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE. Alternative splicing and genomic structure of the Wilms' tumor gene WT1. Proc Natl Acad Sci USA 1991;88:9618-9622.
4. Pritchard-Jones K, Fleming S, Davidson D, Bickmore W, Porteus D, Gosden C, Bard J, et al. The candidate Wilms' tumor gene is involved in genitourinary development. Nature 1990;346:194-197.
5. Madden SL, Cook D, Rauscher F. Transcriptional repression mediated by the WT1 Wilms' tumor gene product. Science 1991;253:1550-1553.
6. Little M, Wells C. A clinical overview of WT1 gene mutations. Hum Mutat 1997;9:209-225.
7. Pelletier J, Bruening W, Kashtan C, Mauer S, Manivel J, Striegel J, Houghton D, et al. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 1991;67:437-447.
8. Barbaux S, Niaudet P, Gubler MC, Grunfeld JP, Jaubert F, Kuttenn F, Fekete CN, Souleyreautherville N, Thibaud E, Fellous M, McElreavey K. Donor splice-site mutations in WT1 are responsible for Frasier-syndrome. Nature Genet 1997;17:467-470.
9. Ladanyi M, Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res 1994;12:350-359.
10. King-Underwood L, Renshaw J, Pritchard-Jones K. Mutations in the Wilms' Tumour gene WT1 in leukemias. Blood 1996;87:2171-2179.
11. Larsson SH, Charlieu J-P, Miyagawa K, Engelkamp D, Rassoulzadegan M, Ross A, Cuzin F, et al. Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell 1995;81:391-401.
12. Armstrong JF, Pritchard-Jones K, Bickmore WA, Hastie ND, Bard JB. The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo. Mech Dev 1992;40:85-97.
13. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, Jaenisch R. WT-1 is required for early kidney development. Cell 1993;74: 679-691.
14. Stark K, Vainio S, Vassileva G, McMahon AP. Epithelial transformation of metanephric mesenchyme in the developing kidney regulated by Wnt-4. Nature 1994;372:679-683.
15. Ryan G, Steele-Perkins V, Morris JF, Rauscher FJ, Dressler GR. Repression of Pax-2 by WT1 during normal kidney development. Development 1995;121:867-875.
16. McConnell MJ, Cunliffe HE, Chua LJ, Ward TA, Eccles MR. Differential regulation of the human Wilms-tumour suppressor gene (WT1) promoter by two isoforms of Pax2. Oncogene 1997;14:2689-2700.
17. Jadresic L, Leake J, Gordon I, Dillon MJ, Grant DB, Pritchard J, Risdon RA, Barratt TM. Clincopathologic review of twelve children with nephropathy. Wilms' tumor and genital abnormalities (Drash syndrome). J Pediatr 1990;117:717-725.
18. Huff V. Evidence for WT1 as a Wilms tumor (WT) gene: intragenic germinal deletion in bilateral WT. Am J Hum Genet 1991;48:997-1003.
19. Denys P, Malvaux P, van den Berghe H, Tanghe W, Proesmans W. De pseudohermaphrodisme masculin, d'une tumeur de Wilms, d'une nephropathie parenchy-mateuse et d'un mosaicisme XX/XY. Arch Fr Pediatr 1967;24:729-739.
20. Drash A, Sherman F, Hartmann W, Blizzard R. A syndrome of pseudohermaphroditism, Wilms' tumor, hypertension and degenerative renal disease. J Pediatr 1970;76:585-593.
21. Little MH, Williamson KA, Mannens M, Kelsey A, Gosden C, Hastie ND, van Heyningen V. Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominant-negative fashion. Hum Mol Genet 1993;2:259-264.
22. Little M, Holmes G, Bickmore W, van Heyningen V, Hastie N, Wainwright B. DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations. Hum Mol Genet 1995;4:351-358.
23. Jeanpierre C, Denamur E, Henry I, Cabanis MO, Luce S, Cecille A, Elion J, Peuchmaur M, Loirat C, Niaudet P, Gubler MC, Junien C. Identification of constitutional WT1 mutations, in patients with isolated diffuse mesangial sclerosis, and analysis of genotype/phenotype correlations by use of a computerized mutation database. Am J Hum Genet 1998;62:824-833.
24. Bickmore WA, Oghene K, Little MH, Seawright A, Van Heyningen V, Hastie ND. Modulation of DNA binding specificity by alternative splicing of the Wilms tumor wt1 gene transcript. Science 1992;257:235-237.
25. Nakagama H, Heinrich G, Pelletier J, Housman DE. Sequence and structural requirements for high-affinity DNA binding by the WT1 gene product. Mol Cell Biol 1995;15:1489-1498.
26. Reddy JC, Licht JD. The WT1 Wilms' tumor suppressor gene: how much do we really know? Biochim Biophys Acta Rev Cancer 1995;1287:1-28.
27. Wang Z, Qiu Q, Deuel T. The Wilms' tumour gene product WT1 activates or supresses transcription through separate functional domains. J BiolChem 1993;268:9172-9175.
28. Wang Z, Qiu Q, Enger K, Deuel T. A second transcriptionally active DNA-binding site for the Wilms' tumour gene product, WT1. Proc Natl Acad Sci USA 1993;90:8896-8900.
29. Rupprecht H, Drummond I, Madden S, Rauscher F, Sukhatme V. The Wilms' tumour suppressor gene WT1 is negatively autoregulated. J Biol Chem 1994;269:6198-6206.
30. Vicanek C, Ferretti E, Goodyer C, Torban E, Moffett P, Pelletier J, Goodyer P. Regulation of renal EGF receptor expression is normal in Denys-Drash syndrome. Kidney Int 1997;52:614-619.
31. Bergmann L, Maurer U, Weidmann E. Wilms tumor gene expression in acute myeloid leukemias [review] Leukemia Lymphoma 1997;25:435-443.
32. Moss T, Strauss L, Das L, Feig S. Secondary leukemia following successful treatment of Wilms' tumor. Am J Pediatr Hematol Oncol 1989;11:158-161.
33. Baird PN, Simmons PJ. Expression of the Wilms tumor gene (WT1) in normal hemopoiesis. Exp Hematol 1997;25:312-320.
34. Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E, Hoelzer D. High levels of Wilms-tumor gene (WT1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome Blood 1997;90: 1217-1225.
35. King-Underwood L, Pritchard-Jones K. Wilms tumor (WT1) gene mutations occur mainly in acute myeloid leukemia anc may confer drug resistance. Blood 1998;91:2961-2968.
36. Brieger J, Wiedemann E, Fenchel K, Mitrou P, Hoelzer D, Bergmann L. The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia 1994;8:2138-2143.
37. Carapeti M, Goldman JM, Cross NCP. Dominant-negative mutations of the Wilms tumour predisposing gene (WT1) are infrequent in CML blast crisis and de novo acute leukaemia. Eur J Haematol 1997;58:346-349.
38. Schmid D, Heinze G, Linnerth B, Tistjar K, Kusec R, Geissler K, Sillaber C, Laczika K, Mitterbauer M, Zochbauer S, Mannhalter C, Haas OA, Lechner K, Jager U, Gaiger A. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 1997;11: 639-643.
39. Algar EM, Khromykh T, Smith SI, Blackburn DM, Bryson GJ, Smith PJ. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in lyeloid leukemia cell lines. Oncogene 1996;12:1005-1014.
40. Yamagami T, Ogawa H, Tamaki H, Oji Y, Soma T, Oka Y, Tatekawa T, Tsuboi A, Kim EH, Akiyama T, Sugiyama H. Suppression of Wilms tumor gene (WT1) expression induces G(2)/M arrest in leukemic cells. Leukemia Res 1998;22:383-384.
41. Lee SB, Kolquist KA, Nichols K, Englert C, Maheswaran S, Ladanyi M, Gerald WL, Haber DA. The EWS - WT1 translocation product induces PDGFA in desmoplastic small round-cell lumour. Nature Genet 1997;17: 309-313.
42. Caricasole A, Duarte A, Larsson S, Hastie ND, Little M, Holmes G, Todorov I, Ward A. RNA binding by the Wilms' tumor suppressor (WT1) zinc finger proteins. Proc Natl Acad Sci USA 1996;93:7562-7566.
43. Bardeesy N, Pelletier J. Overlapping RNA and DNA binding domains of the WT1 tumor suppressor gene product. Nucleic Acids Res 1998;26: 1784-1792.
44. Kennedy D, Ramsdale T, Mattick J, Little M. An RNA recognition motif in WT1 revealed by structural modelling. Nature Genet 1996;12:329-332.
45. Kent J, Coriat A-M, Hastie ND, van Heyningen V. The evolution of WT1 sequence and expression pattern in vertebrates. Oncogene 1995;11:1781-1792
46. Oubridge C, Ito N, Evans PR, Teo CH, Nagai K. Crystal structure at 1.92A resolution of the RNA-binding domain of the U1A spliceosomal protein complexed with an RNA hairpin. Nature 1994;372:432-438.
47. Nagai K, Mattaj IW. RNA-protein interactions. Oxford, UK: IRL Press. 1994.
48. Reddy JC, Morris JC, Wang J, English MA, Haber DA, Shi Y, Licht JD. WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins. J Biol Chem 1995;270:10878-10884.
49. Ladomery M. Multifunctional proteins suggest connections between transcriptional and post-transcriptional processes. BioEssays 1997;19: 903-909.
50. Matsushima Y, Matsumura K, Kitagawa Y. Zinc finger-like motif conserved in a family of RNA binding proteins. Biosci Biotech Biochem 1997;61:905-906.
51. Mattaj IW. Splicing in space Nature 1994;372:727-728.
52. Holmes GP, Boterashvili S, English M, Wainwright BJ, Licht JD, Little M. Two N-terminal self-association domains are required for the dominant negative activity of WT1 Denys-Drash mutant proteins. Biochem Biophys Res Commun 1997;233:723-728.
53. Englert C, Vidal M, Maheswaran S, Ge YM, Ezzell RM, Isselbacher KJ, Haber DA. Truncated WT1 mutants alter the subnuclear localisation of the wild-type protein. Proc Natl Acad Sci USA 1995;92:11960-11964.
54. Maheswaran S, Park S, Bernard A, Morris J, Rauscher F, Hill D, Haber D. Physical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci USA 1993;90:5100-5104.
55. Johnstone RW, See RH, Sells SF, Wang J, Muthukkumar S, Englert C, Haber DA, Licht JD, Sugrue SP, Roberts T, Rangneka VM, Shi Y. A novel represser, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol 1996;16:6945-6956.
56. Johnstone RW, Wang J, Tommerup N, Vissing H, Roberts T, Shi Y. Ciao 1 is a novel WD40 protein that interacts with the tumor suppressor protein WT1. J Biol Chem 1998;273:10880-10887.
57. Maheswaran S, Englert C, Zheng G, Lee SB, Wong J, Harkin DP, Bean J, Ezzell R, Garvin AJ, McCluskey RT, Decaprio JA, Haber DA. Inhibition of cellular proliferation by the Wilms tumor suppressor. WT1, requires association with the inducible chaperone Hsp70. Genes Dev 1998;12 1108-1120.
58. Nachtigal MW, Hirokawa Y, Enyeartvanhouten DL, Flanagan JN, Hammer GD, Ingraham HA. Wilms tumor 1 and DAX-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression. Cell 1998;93:445-454.
59. Werner H, Rauscher FJ, Sujhatme VP. Drummond IA. Roberts CT, LeRoith D. Transcriptional repression of the insulin-like growth factor 1 receptor (IGF1R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF1R gene transcription start site. J Biol Chem 1994;269:12577-12582.
60. Englert C, Hou X, Maheswaren S, Bennett P, Ngwu C, Re GG, Garvin AJ, Rosner MR, Haber D. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J 1995;14:4662-4675.
61. Goodyer P, Dehbi M, Torban E, Bruening W, Pelletier J. Repression of the retinoic acid receptor-α gene by the Wilms' tumor suppressor gene product. WT1. Oncogene 1995;10:1125-1129.
62. Webster NJG, Kong Y, Sharma P, Haas M, Sukumar S, Seely BL. Differential effects of wilms-tumor WT1 splice variants on the insulin receptor promoter. Biochem Mol Med 1997;62:139-150.
63. Hewitt SM, Saunders GF. Differentially spliced exon 5 of the Wilms' tumor gene WT1 modifies gene function. Anticancer Res 1996;16:621-626.
64. McCann S, Sullivan J, Guerra J, Arcinas M, Boxer LM. Repression of the c-myb gene by WT1 protein in T and B cells. J Biol Chem 1995;270:23785-23789.
65. Hewitt SM, Hamada S, McDonnell TJ, Rauscher F III. Saunders GF. Regulation of the proto-oncogenes Bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res 1995;55:5386-5389.
66. Miyagawa K, Kent J, Moore A, Charlieu JP, Little MH, Williamson KA, Kelsey A, Brown KW, Hassam S, Briner J, Hayashi Y, Hirai H, Yazaki Y, Vanheyningen V, Hastie ND. Loss of WT1 function leads to ectopic myogenesis in Wilms tumour. Nature Genet 1998;18:15-17.
67. Ward A, Pooler JA, Miyagawa K, Duarte A, Hastie ND, Cancasole A. Repression of promoters for the mouse insulin-like growth factor II-encoding gene (lgf2) by products of the Wilms' tumour suppressor gene WT1. Gene 1995;167:239-243.
68. Wang ZY, Madden SL, Deuel TF, Rauscher FJ III. The Wilms' tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene. J Biol Chem 1992;267:21999-2002.
69. Dey BR, Sukhatme VP, Roberts AB, Sporn MB, Rauscher FJ III, Kim SJ. Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product. Mol Endocrinol 1994;8:595-602.
70. Harrington MA, Konicek B, Song A, Xia X-L, Fredericks WJ, Rauscher FJ. III. Inhibition of the colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus. J Biol Chem 1993;268:21271-21275.
71. Hsu SY, Kubo M, Chun SY, Haluska FG, Housman DE, Hsueh AJ. Wilms' tumor protein WT1 as an ovarian transcription factor: decreases in expression during follicle development and repression of inhibin-alpha gene promoter. Mol Endocrinol 1995;9:1356-1366.
72. Cook DM, Hinkes MT, Bernfield M, Rauscher F. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1. Oncogene 1996;272:2901-2913.
73. Adachi Y, Matsubara S, Pedraza C, Ozawa M, Tsutsui J, Takamatsu H, Noguchi H, Akiyama T, Muramatsu T. Midkine as a novel target for the Wilms' tumour suppressor gene (WT1). Oncogene 1996;13:2197-2203.
74. Moshier JA, Skunca M, Wu W, Boppana SM, Rauscher F, Dosescu J. Regulation of ornithine decarboxylase gene expression by the Wilms' tumor suppressor WT1. Nucleic Acids Res 1996;24:1149-1157.
75. Martinerie C, Chevalier G, Rauscher F, Perbal B. Regulation of nov by WT1: a potential role for nov in nephrogenesis. Oncogene 1996;12:1479-1492.
76. Kinane TB, Finder JD, Kawashima A, Brown D, Abbate M, Fredericks WJ, Sukhatme VP, Rauscher FJ III, Ercolani L. LLC-PK1 cell growth is repressed by WT1 inhibition of G-protein alpha i-2 protooncogene transcription. J BiolChem 1996;271:30760-30764.
77. Reddy JC, Hosono S, Licht JD. The transcriptional effect of WT1 is modulated by choice of expression vector. J Biol Chem 1995;270:29976-29982.
78. Haber D, Park S, Maheswaran S, Englert C, Re G, Hazen Martin D, Sens D, Garvin A. WT1-mediated growth suppression of Wilms' tumor cells expressing a WT1 splicing variant. Science 1993;262:2057-2059.
79. Menke AL, Riteco N, Vanham RC, Rauscher F, van der Eb AJ, Jochemsen AG. Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells. Oncogene 1996; 12:537-546.
80. Smith SI, Weil D, Johnson GR, Boyd AW, Li CL. Expression of the Wilms tumor suppressor gene, WT1, is upregulated by leukemia inhibitory factor and induces monocytic differentiation in M1 leukemic cells. Blood 1998;91: 764-773.
81. Svedberg H, Chylicki K, Baldetorp B, Rauscher FJ, Gullberg U. Constitutive expression of the Wilms tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program. Oncogene 1998;16:925-932.
82. Kudoh T, Ishidate T, Moriyama M, Toyoshima K, Akiyama T. G1 phase arrest induced by Wilms' tumor protein WT1 is abrogated by cyclin/CDK complexes. Proc Natl Acad Sci USA 1995;92:4517-4521.
83. Murata Y, Kudoh T, Sugiyama H, Toyoshima K, Akiyama T. The Wilms Tumor suppressor gene WT1 induces G1 arrest and apoptosis in myeloblastic leukemia M1 cells 1997 FEBS Lett 409:41-45.
84. Maheswaran S, Englert C, Bennett P, Heinrich G, Haber DA. The WT1 gene product stabilises p53 and inhibits p53-mediated apoptosis. Genes Dev 1995;9:2143-2156.
85. Kudoh T, Ishidate T, Nakamura T, Toyoshima K, Akiyama T. Constitutive expression of the Wilms tumor suppressor gene WT1 in F9 embryona: carcinoma cells induces apoptotic cell death in response to retinoic acid. Oncogene 1996;13:1431-1439.
86. Wang ZY, Qiu QQ, Seufert W, Taguchi T, Testa JR, Whitmore SA, Callen DF, Welsh D, Shenk T, Deuel TF. Molecular cloning of the cDNA and chromosomal localisation of the gene for the human ubiquitin-conjugating enzyme 9. J Biol Chem 1996;271:24811-24816.
87. Davis RC, Calvo C, Bratt E, Larsson SH, Lamond AI, Hastie ND. WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes. Genes Dev 1998;12(20): 3217-25.